October 23, 2020 Drug Utilization Review Board (DURB) Agenda
»
1. Call to order
1. Call to order
»
2. Approval of minutes from July 24, 2020 (vote required)
2. Approval of minutes from July 24, 2020 (vote required)
»
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Androgenic agents b. Antibiotics, gastrointestinal (GI) c. Antibiotics, topical d. Antibiotics, vaginal e. Antiemetics/Antivertigo agents f. Antifungals, oral g. Antifungals, topical h. Antihistamines - first generation i. Antiparasitics, topical j. Antipsychotics k. Antivirals, topical l. Bone resorption suppression and related agents m. Colony stimulating factors n. Epinephrine, self-injected o. GI motility, chronic p. Growth hormone q. Hepatitis C agents r. Hypoglycemics, incretin mimetics/enhancers s. Hypoglycemics, insulin and related t. Hypoglycemics, meglitinides u. Hypoglycemics, metformin v. Hypoglycemics, sodium-glucose cotranporter-2 inhibitors (SLGT2) w. Hypoglycemics, thiazolidinedione (TZD) x. Macrolides-Ketolides y. Opiate dependence treatments z. Tetracyclines
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Androgenic agents b. Antibiotics, gastrointestinal (GI)
c. Antibiotics, topical
d. Antibiotics, vaginal
e. Antiemetics/Antivertigo agents
f. Antifungals, oral
g. Antifungals, topical
h. Antihistamines - first generation
i. Antiparasitics, topical
j. Antipsychotics
k. Antivirals, topical
l. Bone resorption suppression and related agents
m. Colony stimulating factors
n. Epinephrine, self-injected
o. GI motility, chronic
p. Growth hormone
q. Hepatitis C agents
r. Hypoglycemics, incretin mimetics/enhancers
s. Hypoglycemics, insulin and related
t. Hypoglycemics, meglitinides
u. Hypoglycemics, metformin
v. Hypoglycemics, sodium-glucose cotranporter-2 inhibitors (SLGT2)
w. Hypoglycemics, thiazolidinedione (TZD)
x. Macrolides-Ketolides
y. Opiate dependence treatments
z. Tetracyclines
»
4. Public comment on new drugs to be reviewed for the Medicaid Preferred Drug List » - a. Benzefoam foam over-the-counter (OTC) (topical) / Acne agents, topical b. Dupixent pen (subcutaneous) / Immunomodulators, atopic dermatitis c. Nexlizet (oral) / Lipotropics, other d. Voltaren gel OTC (topical) / NSAIDs e. Dayvigo (oral) / Sedative hypnotics
4. Public comment on new drugs to be reviewed for the Medicaid Preferred Drug List »
a. Benzefoam foam over-the-counter (OTC) (topical) / Acne agents, topical b. Dupixent pen (subcutaneous) / Immunomodulators, atopic dermatitis
c. Nexlizet (oral) / Lipotropics, other
d. Voltaren gel OTC (topical) / NSAIDs
e. Dayvigo (oral) / Sedative hypnotics
»
5. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
5. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
»
6. Executive work session
6. Executive work session
»
7. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
7. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
»
8. Retrospective DUR: Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Non-steroidal anti-inflammatory drugs (NSAIDs) drug use evaluation (DUE) ii. Asthma management iii. Pharmacotherapy of post-traumatic stress disorder (PTSD) b. Report on recent retrospective DUR intervention outcomes: i. Treatment with opioids, benzodiazepines, and antipsychotics c. Retrospective DUR proposals: (vote required) i. Anticonvulsants DUE ii. Comprehensive opioid management iii. Management of psychotropic drugs in youth
8. Retrospective DUR: Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Non-steroidal anti-inflammatory drugs (NSAIDs) drug use evaluation (DUE)
ii. Asthma management
iii. Pharmacotherapy of post-traumatic stress disorder (PTSD)
b. Report on recent retrospective DUR intervention outcomes:
i. Treatment with opioids, benzodiazepines, and antipsychotics
c. Retrospective DUR proposals: (vote required)
i. Anticonvulsants DUE
ii. Comprehensive opioid management
iii. Management of psychotropic drugs in youth
»
9. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) » - a. Evrysdi (oral solution) – new criteria b. Calcitonin gene-related peptide receptor (CRGP) antagonists, acute Nurtec/Ubrelvy - new criteria c. Oriahnn (capsules)- new criteria d. Vyvanse (capsules/chewable tablets)- revised criteria e. Wakix (tablets) – new criteria f. Xywav (oral solution) – new criteria
9. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) »
a. Evrysdi (oral solution) – new criteria b. Calcitonin gene-related peptide receptor (CRGP) antagonists, acute Nurtec/Ubrelvy - new criteria
c. Oriahnn (capsules)- new criteria
d. Vyvanse (capsules/chewable tablets)- revised criteria
e. Wakix (tablets) – new criteria
f. Xywav (oral solution) – new criteria
»
10. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) » - a. Anti-diabetic agents (oral) b. Attention Deficit Disorder / Attention Deficit Hyperactivity Disorder c. Glucagon peptide-like 1 receptor agonists d. Pramlintide e. Serotonin 5-HT3 receptor antagonists for nausea and vomiting (oral) f. Substance P/Neurokinin1 receptor antagonists
10. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) »
a. Anti-diabetic agents (oral) b. Attention Deficit Disorder / Attention Deficit Hyperactivity Disorder
c. Glucagon peptide-like 1 receptor agonists
d. Pramlintide
e. Serotonin 5-HT3 receptor antagonists for nausea and vomiting (oral)
f. Substance P/Neurokinin1 receptor antagonists
»
Items 11 & 12 » - 11. Next meeting date: January 22, 2021 12. Adjourn – Day Two
Items 11 & 12 »
11. Next meeting date: January 22, 2021 12. Adjourn – Day Two
